Zynex, Inc. is a medical device manufacturer that produces and markets electrotherapy devices for use in pain management, physical rehabilitation, neurological diagnosis and cardiac monitoring. Thomas Sandgaard founded Zynex Medical in 1996.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| ZYXI | ZYNEX INC | 2025-10-30 18:04:43 | 1.14 | -0.11 | -8.8 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZYXI | 0000846475 | ZYNEX INC | US98986M1036 | — | 870403828 | Nasdaq | 3845 | Electromedical & Electrotherapeutic Apparatus | 1231 | NV | 9655 MAROON CIRCLE | ENGLEWOOD | CO | 80112 | UNITED STATES | US | (800)-495-6670 | 9655 MAROON CIRCLE, ENGLEWOOD, CO, 80112 | 9655 MAROON CIRCLE, ENGLEWOOD, CO, 80112 | ZYNEX MEDICAL HOLDINGS INC | — | 1996 | — | 1,100 | http://zynex.com | 143,400,000 | 42,308,325 | 30,297,442 | Zynex, Inc. is a medical device manufacturer that produces and markets electrotherapy devices for use in pain management, physical rehabilitation, neurological diagnosis and cardiac monitoring. Thomas Sandgaard founded Zynex Medical in 1996. | 2025-10-30 16:56:20 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 143,400,000 | -61,800,000 | -30.117 | 31,912,487 | -257,695 | -0.801 |
| 2023 | 205,200,000 | 30,000,000 | 17.1233 | 32,170,182 | -4,464,277 | -12.186 |
| 2022 | 175,200,000 | -132,400,000 | -43.0429 | 36,634,459 | -3,149,609 | -7.9168 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Daniel Moorhead | Chief Financial Officer | 2024 | 415,000 | 125,000 | 304,158 | 33,719 | 31,928 | 909,805 |
| Anna Lucsok | Chief Operating Officer | 2024 | 300,000 | 100,000 | 245,374 | 48,750 | 14,985 | 709,109 |
| Thomas Sandgaard | Chief Executive Officer, Chairman, President | 2024 | 700,000 | 0 | 112,458 | 170,625 | 8,727 | 991,810 |
| Thomas Sandgaard | Chief Executive Officer, Chairman, President | 2023 | 650,000 | 0 | 225,065 | 304,688 | 38,142 | 1,217,895 |
| Daniel Moorhead | Chief Financial Officer | 2023 | 325,000 | 0 | 410,540 | 50,781 | 96,825 | 883,146 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 1,000 |
| 2023 | 1,100 |
| 2022 | 900 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 192,354,000 | 184,322,000 | 158,167,000 |
| Cost Of Revenue | 39,429,000 | 38,366,000 | 32,005,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 12,000,000 | 9,200,000 | 7,100,000 |
| General And Administrative Expenses | 60,354,000 | 48,517,000 | 36,108,000 |
| Operating Expenses | 186,364,000 | 173,542,000 | 135,229,000 |
| Operating Income | 5,990,000 | 10,780,000 | 22,938,000 |
| Net Income | 2,994,000 | 9,732,000 | 17,048,000 |
| Earnings Per Share Basic | 0.09 | 0.27 | 0.44 |
| Earnings Per Share Diluted | 0.09 | 0.27 | 0.44 |
| Weighted Average Shares Outstanding Basic | 31,941,000 | 35,555,000 | 38,467,000 |
| Weighted Average Shares Outstanding Diluted | 32,299,000 | 36,142,000 | 39,127,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 39,631,000 | 44,579,000 | 20,144,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | 18,022,000 | 26,838,000 | 35,063,000 |
| Inventories | 13,919,000 | 13,106,000 | 13,484,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 75,179,000 | 87,855,000 | 69,559,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 3,084,000 | 3,114,000 | 2,175,000 |
| Other Assets Non Current | — | — | — |
| Total Assets Non Current | 46,900,000 | 49,049,000 | 46,907,000 |
| Total Assets | 122,079,000 | 136,904,000 | 116,466,000 |
| Accounts Payable | 7,091,000 | 8,433,000 | 5,601,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | — | — | 5,333,000 |
| Other Liabilities Current | — | 633,000 | 1,995,000 |
| Total Liabilities Current | 16,864,000 | 18,532,000 | 21,086,000 |
| Long Term Debt | 58,567,000 | 57,605,000 | 5,293,000 |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | 69,507,000 | 72,243,000 | 29,022,000 |
| Total Liabilities | 86,371,000 | 90,775,000 | 50,108,000 |
| Common Stock | 32,000 | 33,000 | 39,000 |
| Retained Earnings | 29,774,000 | 26,780,000 | 17,048,000 |
| Accumulated Other Comprehensive Income | — | — | — |
| Total Shareholders Equity | 35,708,000 | 46,129,000 | 66,358,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 2,901,000 | 2,684,000 | 2,197,000 |
| Share Based Compensation Expense | 2,989,000 | 2,296,000 | 2,342,000 |
| Other Non Cash Income Expense | 19,000 | 39,000 | — |
| Change In Accounts Receivable | -8,816,000 | -8,225,000 | 6,430,000 |
| Change In Inventories | 2,736,000 | 1,445,000 | 4,320,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -2,072,000 | 269,000 | 1,834,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | 12,721,000 | 17,756,000 | 13,746,000 |
| Purchases Of Marketable Securities | — | 9,810,000 | — |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 578,000 | 1,206,000 | 418,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -578,000 | -966,000 | -418,000 |
| Tax Withholding For Share Based Compensation | 672,000 | 737,000 | 352,000 |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | 15,625,000 | 38,405,000 | 26,650,000 |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | 10,667,000 | 5,333,000 |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | -17,091,000 | 7,645,000 | -35,796,000 |
| Change In Cash | -4,948,000 | 24,435,000 | -22,468,000 |
| Cash At End Of Period | 39,631,000 | 44,579,000 | 20,144,000 |
| Income Taxes Paid | -2,582,000 | -6,456,000 | -6,294,000 |
| Interest Paid | — | 739,000 | 391,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | 0.09 | 0.27 | 0.44 |
| Price To Earnings Ratio | 89 | 40.3333 | 31.6136 |
| Earnings Growth Rate | -66.6667 | -38.6364 | -2.2222 |
| Price Earnings To Growth Ratio | -1.335 | -1.0439 | -14.2261 |
| Book Value Per Share | 1.1179 | 1.2974 | 1.7251 |
| Price To Book Ratio | 7.165 | 8.3937 | 8.0635 |
| Ebitda | 6,313,000 | 4,866,000 | 12,511,000 |
| Enterprise Value | 274,783,410 | 400,219,950 | 525,557,970 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 1.6402 | 1.2488 | 0.1601 |
| Capital Expenditures | 2,871,000 | 3,623,000 | 2,186,000 |
| Free Cash Flow | 9,850,000 | 14,133,000 | 11,560,000 |
| Return On Equity | 0.0838 | 0.211 | 0.2569 |
| One Year Beta | 0.8954 | 1.4011 | 1.0991 |
| Three Year Beta | 1.1026 | 1.0885 | 1.0058 |
| Five Year Beta | 1.0274 | 1.016 | 0.9096 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Lucsok Anna | CHIEF OPERATING OFFICER | 2025-07-28 | 3,793 | D | 40,856 |
| Lucsok Anna | CHIEF OPERATING OFFICER | 2025-07-27 | 7,500 | A | 64,412 |
| MOORHEAD DANIEL J | CHIEF FINANCIAL OFFICER | 2025-06-05 | 3,982 | D | 16,273 |
| MOORHEAD DANIEL J | CHIEF FINANCIAL OFFICER | 2025-06-05 | 5,000 | A | 64,245 |
| Cress Michael D | Director | 2025-05-15 | 10,000 | A | 22,500 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| True Wealth Design, LLC | 2025-09-30 | 108 | 74 | 1.4595 |
| Fortitude Family Office, LLC | 2025-09-30 | 348 | 240 | 1.45 |
| Alhambra Investment Management LLC | 2025-09-30 | 18,125 | 12,500 | 1.45 |
| Farther Finance Advisors, LLC | 2025-09-30 | 15 | 10 | 1.5 |
| OSAIC HOLDINGS, INC. | 2025-06-30 | 644 | 250 | 2.576 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| AMERICAN CENTURY ETF TRUST | 2025-08-31 | Avantis U.S. Small Cap Equity ETF | AVSC | 8,910 | 14,612.4 | 0.0008 |
| AMERICAN CENTURY ETF TRUST | 2025-08-31 | Institutional Class | AVSBX | 182 | 298.48 | 0.0003 |
| AMERICAN CENTURY ETF TRUST | 2025-08-31 | G Class | AVSCX | 182 | 298.48 | 0.0003 |
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Series Total Market Index Fund | FCFMX | 21,213 | 34,789.32 | 0.0 |
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Total Market Index Fund | FSKAX | 29,060 | 47,658.4 | 0.0 |